Catheter Precision Inc VTAK

Healthcare Medical Devices

Catheter Precision, Inc. is a medical device company. It is engaged in providing new solutions to the market to improve the treatment of cardiac arrhythmias. It is focused on developing technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. It is also focused on developing and delivering electrophysiology products to provide patients, hospitals, and physicians with novel technologies and solutions to improve the lives of patients with cardiac arrhythmias. Its product is the VIVO System, which is an anacronym for View into Ventricular Onset System, which is a non-invasive imaging system that offers three-dimensional cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients. Its LockeT product is a suture retention device indicated for wound healing. Its product portfolio also includes the Amigo Remote Catheter System, a robotic arm that serves as a catheter control device.

NYSEAM:VTAK - Post by User

Catheter Precision Inc

<< Previous

Bullboard Posts

Next >>

Post by AveragePennyon May 07, 2024 8:36am

48 Views

Post# 36026484

Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1...

Operational highlights of the first quarter and early second quarter 2024 include the following:

Submission of LockeT for CE Mark approval, which is expected in Q3 2024.
First published data on initial LockeT clinical study of over 100 patients presented at Western Atrial Fibrillation Symposium. Data included:
- 100% immediate hemostasis.
- Allows for same day discharge.
- Effective at wound closure up to 27F which includes cardiac catheters and products such as left atrial appendage devices and leadless pacemakers.
- Reduction in the need for multiple closure devices.
Attendance at the European Heart Rhythm Association (EHRA) conference
Attendance at Monaco USA Arrhythmia Conference (MUAC) at which positive interim study data related to VIVO was presented on the accuracy of VIVO when used for ventricular ablation on infarcted hearts by Professor Tarv Dhanjal from University Hospital of Coventry and Warwickshire.
First VIVO procedure in Spain at Hospital Universitario Virgen de las Nieves in Granda with Dr. Pablo J. Sanchez Millan.
First procedures at CHU de Rennes (University Hospital of Rennes) in Rennes, France. This hospital is one of the world's most prolific centers in terms of number of ventricular ablations performed each year.
Presentation of the first cases in Turkey by Professor Cem Karadeniz at the National Arrhythmia Congress Turkiye meeting.
Recruitment and onboarding of US sales and clinical support in new US regions to support the national launch of LockeT and continued expansion of VIVO.
Announced new Chief Commercial Officer, Marie-Claude Jaques, as of May 1, 2024.